Ciudad Autonoma de Buenos Aires
Ciudad Autonoma de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina58 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-09 | NCT07554339 | |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Arrhythmias, Cardiac, Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07175428 | |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07634471 | |
| A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07519772 | |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07060807 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease | Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-08 | NCT07011745 | |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05139017 | |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-10-07 | NCT07220759 | |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Recruiting | Phase 3 | 2026-10-07 | NCT06997497 | |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | endocrine system disorder, hypoparathyroidism, parathyroid gland disorder, thyroid gland disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT06531941 | |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07419295 | |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07318558 | |
| Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-06 | NCT07284901 | |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | cancer, neoplasm | Recruiting | Phase 2 | 2026-10-06 | NCT06979596 | |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT06745323 | |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Familial Primary Pulmonary Hypertension, Skin and Connective Tissue Diseases, cardiovascular disorder, connective tissue disorder, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorder | Enrolling by invitation | Phase 3 | 2026-10-06 | NCT03683186 | |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-05 | NCT04728893 | |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | Branch Vein Occlusion, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, central retinal vein occlusion, diabetic macular edema, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Active, not recruiting | Not stated | 2026-10-02 | NCT05476926 | |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Cholangitis, Sclerosing, Digestive System Diseases, bile duct disorder, biliary tract disorder, cholangitis, primary sclerosing cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT07387549 | |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Squamous Non-small Cell Lung Cancer | Recruiting | Phase 2 | 2026-10-01 | NCT07221474 | |
| A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, urinary system disorder | Recruiting | Phase 3 | 2026-09-30 | NCT06963827 | |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-28 | NCT06937229 | |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06312137 | |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07028853 |